Allogeneic HSCT induces durable response in B-cell lymphoma

SALT LAKE CITY — Patients with relapsed or refractory large B-cell lymphoma who failed chimeric antigen receptor T-cell therapy achieved durable responses with allogeneic hematopoietic stem cell transplantation, according to study results.
The results — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — showed no unexpected or prolonged adverse events with hematopoiesis, as well as no signals of increased graft-versus-host disease risk or other serious complications.
“There are currently three FDA approved CAR T-cell

SALT LAKE CITY — Patients with relapsed or refractory large B-cell lymphoma who failed chimeric antigen receptor T-cell therapy achieved durable responses with allogeneic hematopoietic stem cell transplantation, according to study results.
The results — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — showed no unexpected or prolonged adverse events with hematopoiesis, as well as no signals of increased graft-versus-host disease risk or other serious complications.
“There are currently three FDA approved CAR T-cell